Abstract:Importance: In developed countries, bronchiolitis is the most common reason for infants to be admitted to the hospital, and all international bronchiolitis guidelines recommend supportive care; however, significant variation in practice continues with infants receiving non-evidence-based therapies. Deimplementation research aims to reduce the use of low-value care, and advancing science in this area is critical to delivering evidence-based care. Objective: To determine the effectiveness of targeted interventions vs passive dissemination of an evidence-based bronchiolitis guideline in improving treatment of infants with bronchiolitis. Design, setting, and participants: This international, multicenter cluster randomized clinical trial included 26 hospitals (clusters) in Australia and New Zealand providing tertiary or secondary pediatric care (13 randomized to intervention, 13 to control) during the 2017 bronchiolitis season. Data were collected on 8003 infants for the 3 bronchiolitis seasons (2014-2016) before the implementation period and 3727 infants for the implementation period (2017 bronchiolitis season, May 1-November 30). Data were analyzed from November 16, 2018, to December 9, 2020. Interventions: Interventions were developed using theories of behavior change to target key factors that influence bronchiolitis management. These interventions included site-based clinical leads, stakeholder meetings, a train-the-trainer workshop, targeted educational delivery, other educational and promotional materials, and audit and feedback. Main outcomes and measures: The primary outcome was compliance during the first 24 hours of care with no use of chest radiography, albuterol, glucocorticoids, antibiotics, and epinephrine, measured retrospectively from medical records of randomly selected infants with bronchiolitis who presented to the hospital. There were no patient-level exclusions. Results: A total of 26 hospitals were randomized without dropouts. Analysis was by intention to treat. Baseline data collected on 8003 infants for 3 bronchiolitis seasons (2014-2016) before the implementation period were similar between intervention and control hospitals. Implementation period data were collected on 3727 infants, including 2328 boys (62%) and 1399 girls (38%), with a mean (SD) age of 6.0 (3.2) months. A total of 459 (12%) were Māori (New Zealand), and 295 (8%) were Aboriginal/Torres Strait Islander (Australia). Compliance with recommendations was 85.1% (95% CI, 82.6%-89.7%) in intervention hospitals vs 73.0% (95% CI, 65.3%-78.8%) in control hospitals (adjusted risk difference, 14.1%; 95% CI, 6.5%-21.7%; P < .001). Conclusions and relevance: Targeted interventions led to improved treatment of infants with bronchiolitis. This study has important implications for bronchiolitis management and the development of effective interventions to deimplement low-value care. Trial registration: Australian and New Zealand Clinical Trials Registry: ACTRN12616001567415.

Effect of Immunologic Intervention for Bronchiolitis in Infancy

Expression of IFN-γ,IL-4 and IL-17A in asthmatic mice vaccinated with BCG and HepB in neonatal period

Clinical Observation of Montelukast Prevention for Wheezing Infants and Young Children after Brochiolitis

Effect and security of bronchoalveolar lavage on infected atelectasis in children

Effect and Analysis of Clinical Efficacy of Immunomodulator on Serum Levels of IL-4 and IFN-γ in Asthmatic Children

Therapeutic Effect and Prognostic Evaluation of Atomize Inhaling Glucocorticoid,Terbutaline and Beclomethasone Ipratropine on Bronchiolitis

Effect of BCG-PSN Acupoint Injection on IgE Content and Asthma Control Test Score of Bronchial Asthma

Effect of Low Dose Glucocorticoid Inhalation on Bronchopulmonary Dysplasia in Premature Infants

Effect of nebulized salbutamol and budesonide as an add-on therapy in asthmatic children with respiratory viral infection

Bronchial Asthma Treated with Acupoint Injection of BCG-PSN in Summer:A Randomized Controlled Trial

Efficacy and safety analysis of nebulized recombinant human interferon α1b in treatment of children with bronchiolitis

Preventing Repeated Wheeze Outbreak in Bronchiolitis by Inhaling of Glucocorticoid

Effects of inhaled glucocorticosteroid treatment in airway remodeling in children with bronchial asthma

Effectiveness of Targeted Interventions on Treatment of Infants With Bronchiolitis: A Randomized Clinical Trial

A Comparative Study on Immune Modulatory Effects of Bacilli Calmette-Guérin Polysaccharides Nucleic Acid in Asthma and Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Recombinant Human Interferon α1b Injection Inhaling as Adjuvant Therapy for Bronchiolitis in Infants:A Systematic Review and Meta-analysis

Immunomodulatory Constituents of Human Breast Milk and Immunity from Bronchiolitis

A Multi-Center Randomized Prospective Study on the Treatment of Infant Bronchiolitis with Interferon Α1b Nebulization

Effect of Early Diet Intervention on the Development of Respiratory Allergic Disease in Young Children

The Effect of Nebulized albuterol on Pulmonary Mechanics in Bronchiolitis in Infancy

Clinical inversitgation of beclomethosone in assisted treatment of infant bronchiolitis